论文部分内容阅读
目的 评价国产基因重组IFNα2b单独应用治疗恶性胸、腹水,合并化疗治疗肺癌的近期临床疗效和毒副作用。方法 IFNα2b治疗恶性胸、腹水24例,胸腔注射IFNα2b600MIU/次,腹腔注射900MIU/次,每周2次,共2周。IFNα2b合并MAP或MVP方案化疗治疗肺癌3例,IFNα2b 1MIU每日1次×3d,25例肺癌病人单用MAP或MVP方案化疗。结果 胸、腹水24例,CR5例,PR9例,总有效率为58.33％。其中胸水14例,有效率64.29％,腹水10例,有效率50％。合并化疗治疗肺癌31例,有效率为38.71％,高于单用化疗组(28％),但无统计学显著性。结论 国产IFNα2b胸、腹腔注射治疗恶性胸、腹水有较高的缓解率,合并化疗可能会提高肺癌化疗的近期疗效。
Objective To evaluate the short-term clinical efficacy and toxic side effects of domestically produced recombinant IFNα2b alone in the treatment of malignant chest and ascites, combined with chemotherapy for lung cancer. Methods Twenty-four patients with malignant thoracic and ascites were treated with IFNα2b, intrapleural injection of IFNα2b600MIU/time, intraperitoneal injection of 900MIU/time, 2 times per week for 2 weeks. IFNα2b combined with MAP or MVP regimen chemotherapy in the treatment of lung cancer in 3 cases, IFNα2b 1MIU once a day × 3d, 25 patients with lung cancer alone MAP or MVP chemotherapy. Results There were 24 cases of chest and ascites, 5 cases of CR and 9 cases of PR. The total effective rate was 58.33%. There were 14 cases of pleural effusion, 64.29% of efficiency, 10 cases of ascites, and 50% of efficiency. Thirty-one patients with lung cancer were treated with chemotherapy, and the effective rate was 38.71%, which was higher than that of the chemotherapy alone group (28%), but there was no statistical significance. Conclusion Domestic IFNα2b thoracic and intraperitoneal injection has a higher remission rate in the treatment of malignant chest and ascites. Combining chemotherapy may improve the short-term efficacy of chemotherapy for lung cancer.